Genentech Hemophilia Therapy Gets Solid Endorsement From ICER
Executive Summary
Hemlibra could save health care system $1.85m per patient annually as it displaces current approaches to treatment, Institute for Clinical and Economic Review projects in draft report.
You may also be interested in...
ICER Hemophilia Gene Therapy Reviews Show Clear ‘Net Health Benefit’ But Caution On Patient, Payer Fronts Given Upfront Costs
Restrictive interpretations of FDA labels for BioMarin and CSL Behring products by payers could signal slow launch of gene therapies seeking to supplant existing treatments.
Roctavian’s Durability: For The Price, Payers Wanted Longer-Term Proof Anyway
FDA’s decision to seek two more years of data for BioMarin’s gene therapy for hemophilia A ‘makes perfect sense,’ Harvard Pilgrim Health Care’s Michael Sherman says.
Roche's Hemlibra Priced And Labeled To Beat Competition, Safety Concern
Genentech/Roche's Hemlibra, now FDA-approved for hemophilia A patients with inhibitors, offers a once-weekly injection, impressive efficacy with a safety concern that appears to be manageable, and a price that's at least half the cost of the established prophylaxis regimen.